company background image
3933

United Laboratories International HoldingsSEHK:3933 Stock Report

Market Cap

HK$9.4b

7D

-4.7%

1Y

-24.1%

Updated

26 Oct, 2021

Data

Company Financials +
3933 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance5/6
Financial Health6/6
Dividends2/6

3933 Overview

The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, distribution, and sale of pharmaceutical products.

Price History & Performance

Summary of all time highs, changes and price drops for United Laboratories International Holdings
Historical stock prices
Current Share PriceHK$5.09
52 Week HighHK$5.00
52 Week LowHK$7.60
Beta0.27
1 Month Change0.39%
3 Month Change-10.07%
1 Year Change-24.14%
3 Year Change-6.61%
5 Year Change21.48%
Change since IPO41.00%

Recent News & Updates

Aug 30
Is United Laboratories International Holdings (HKG:3933) Using Too Much Debt?

Is United Laboratories International Holdings (HKG:3933) Using Too Much Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Shareholder Returns

3933HK PharmaceuticalsHK Market
7D-4.7%-2.4%0.4%
1Y-24.1%-12.1%6.7%

Return vs Industry: 3933 underperformed the Hong Kong Pharmaceuticals industry which returned -12.1% over the past year.

Return vs Market: 3933 underperformed the Hong Kong Market which returned 6.7% over the past year.

Price Volatility

Is 3933's price volatile compared to industry and market?
3933 volatility
3933 Beta0.27
Industry Beta0.60
Market Beta1

Stable Share Price: 3933 is less volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 3933's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199013,000n/ahttps://www.tul.com.cn

The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Intermediate Products, Bulk Medicine, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, nervous system drugs, vitamins, and vacant gelatin capsules, as well as API and intermediate products.

United Laboratories International Holdings Fundamentals Summary

How do United Laboratories International Holdings's earnings and revenue compare to its market cap?
3933 fundamental statistics
Market CapCN¥7.70b
Earnings (TTM)CN¥1.12b
Revenue (TTM)CN¥9.19b

6.9x

P/E Ratio

0.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
3933 income statement (TTM)
RevenueCN¥9.19b
Cost of RevenueCN¥5.08b
Gross ProfitCN¥4.10b
ExpensesCN¥2.98b
EarningsCN¥1.12b

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.61
Gross Margin44.67%
Net Profit Margin12.23%
Debt/Equity Ratio24.7%

How did 3933 perform over the long term?

See historical performance and comparison

Dividends

1.9%

Current Dividend Yield

20%

Payout Ratio

Valuation

Is United Laboratories International Holdings undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 3933 (HK$5.09) is trading below our estimate of fair value (HK$26.17)

Significantly Below Fair Value: 3933 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 3933 is good value based on its PE Ratio (6.9x) compared to the Hong Kong Pharmaceuticals industry average (10x).

PE vs Market: 3933 is good value based on its PE Ratio (6.9x) compared to the Hong Kong market (9.6x).


Price to Earnings Growth Ratio

PEG Ratio: 3933 is poor value based on its PEG Ratio (1.4x)


Price to Book Ratio

PB vs Industry: 3933 is good value based on its PB Ratio (0.8x) compared to the HK Pharmaceuticals industry average (1x).


Future Growth

How is United Laboratories International Holdings forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

4.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 3933's forecast earnings growth (4.9% per year) is above the savings rate (1.5%).

Earnings vs Market: 3933's earnings (4.9% per year) are forecast to grow slower than the Hong Kong market (17.6% per year).

High Growth Earnings: 3933's earnings are forecast to grow, but not significantly.

Revenue vs Market: 3933's revenue (6.3% per year) is forecast to grow slower than the Hong Kong market (12.4% per year).

High Growth Revenue: 3933's revenue (6.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 3933's Return on Equity is forecast to be low in 3 years time (11.5%).


Past Performance

How has United Laboratories International Holdings performed over the past 5 years?

55.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 3933 has high quality earnings.

Growing Profit Margin: 3933's current net profit margins (12.2%) are higher than last year (6.4%).


Past Earnings Growth Analysis

Earnings Trend: 3933 has become profitable over the past 5 years, growing earnings by 55.5% per year.

Accelerating Growth: 3933's earnings growth over the past year (104.7%) exceeds its 5-year average (55.5% per year).

Earnings vs Industry: 3933 earnings growth over the past year (104.7%) exceeded the Pharmaceuticals industry 23.8%.


Return on Equity

High ROE: 3933's Return on Equity (12.4%) is considered low.


Financial Health

How is United Laboratories International Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: 3933's short term assets (CN¥9.4B) exceed its short term liabilities (CN¥5.6B).

Long Term Liabilities: 3933's short term assets (CN¥9.4B) exceed its long term liabilities (CN¥1.1B).


Debt to Equity History and Analysis

Debt Level: 3933's debt to equity ratio (24.7%) is considered satisfactory.

Reducing Debt: 3933's debt to equity ratio has reduced from 81.8% to 24.7% over the past 5 years.

Debt Coverage: 3933's debt is well covered by operating cash flow (78%).

Interest Coverage: 3933 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is United Laboratories International Holdings's current dividend yield, its reliability and sustainability?

1.91%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 3933's dividend (1.91%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.24%).

High Dividend: 3933's dividend (1.91%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.8%).


Stability and Growth of Payments

Stable Dividend: 3933's dividend payments have been volatile in the past 10 years.

Growing Dividend: 3933's dividend payments have fallen over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (19.6%), 3933's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: 3933's dividends in 3 years are forecast to be thoroughly covered by earnings (13.6% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

10.9yrs

Average board tenure


CEO

United Laboratories International Holdings has no CEO, or we have no data on them.


Board Members

Experienced Board: 3933's board of directors are seasoned and experienced ( 10.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

The United Laboratories International Holdings Limited's employee growth, exchange listings and data sources


Key Information

  • Name: The United Laboratories International Holdings Limited
  • Ticker: 3933
  • Exchange: SEHK
  • Founded: 1990
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$9.368b
  • Shares outstanding: 1.84b
  • Website: https://www.tul.com.cn

Number of Employees


Location

  • The United Laboratories International Holdings Limited
  • 6 Fuk Wang Street
  • Yuen Long Industrial Estate
  • Yuen Long
  • New Territories
  • Hong Kong

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/26 16:23
End of Day Share Price2021/10/26 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.